CN101023918A - Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone - Google Patents
Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone Download PDFInfo
- Publication number
- CN101023918A CN101023918A CNA2006102013942A CN200610201394A CN101023918A CN 101023918 A CN101023918 A CN 101023918A CN A2006102013942 A CNA2006102013942 A CN A2006102013942A CN 200610201394 A CN200610201394 A CN 200610201394A CN 101023918 A CN101023918 A CN 101023918A
- Authority
- CN
- China
- Prior art keywords
- platinum
- acid
- copolymer
- slow
- hydrocortisone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to an anti-cancer compound containing platinum compound and glucocorticoid. It is characterized by that said medicine compound is slow-release injection or slow-release implanlation preparation. The slow-release injection is formed from slow-release microsphere and solvent, the solvent is a special solvent containing suspension adjuvant, the glucocorticoid can be selected from cortisone, prednisone, prednisolone, methyl prednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, fluocinonide, belcomethasone or halometasone, and the platinum compound can be selected from cisplatin, carboplatin, spiroplatin or oxaliplatin, etc. and the slow-release auxiliary material is PLA and its compolymer.
Description
(1) technical field
The present invention relates to a kind of anticancer sustained-release agent that contains glucocorticoid, belong to technical field of pharmaceuticals.Particularly, the invention provides a kind of slow releasing injection and sustained-release implant that contains glucocorticoid.
(2) background technology
Therefore the operative treatment of cancer can not be removed the oncocyte that is dispersed in, and often recurs or causes tumor cell to stimulate diffusion transfer because of operation; Radiotherapy and traditional chemotherapy are not had a selectivity, and be difficult to tumor by local and form effective drug level or therapeutic dose, weak effect, toxicity is big, improves the restriction that medicine or radiological dose are subjected to general toxic reaction again merely.Referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves such as hole, (Kong Q et al., J Surg Oncol.1998 Oct in 1998; 69 (2): 76-82).
The cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth "; referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf; 2004 (Liang Y; et al., Int JCancer.2004; 111 (4): 484-93).
The local placement of antitumor drug can overcome above defective preferably, not only can obviously improve the drug level of tumor by local, and can significantly reduce general toxic reaction.A large amount of internal and external tests have demonstrated the therapeutic effect to entity tumor, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves such as Kong Qingzhongs, (Kong Q et al., J Surg Oncol.1998 Oct in 1998; 69 (2): 76-82) and Kong Qingzhong etc. " place cisplatin in the tumor and cure the former carbuncle in the occipital region tumor of rat " " surgery tumor magazine " 64 phase 268-273 pages or leaves (1997) (Kong Q et al., JSurg Oncol.1997 Oct; 64:268-273).Also can be referring to Chinese patent (ZL00111093.4; ZL96115937.5; Application number 001111264,001111272) and U.S.'s patent of invention (patent No. 6,376,525B1; 5,651,986; 5,626,862).
Yet, the tumor cell of composition such as the blood vessel in the mesenchyma stroma of tumors and fibrin in the connective tissue and collagen protein and hyperplasia cause entity tumor between matter pressure (interstitiai pressure) height, the local placement of antitumor drug often causes the local organization edema.The local organization edema can influence wound healing, increases post-operative complication.The increasing of local pressure also can quicken medicine prominent release and tumor in removing, be unfavorable for keeping of active drug concentration in the tumor.The edema that occurs in significant points (as brain) also can cause severe complications such as cerebral hernia, therefore constitutes the major obstacle that tumor is implanted chemotherapy, causes the treatment failure.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of new pharmaceutical composition is provided, contain glucocorticoid and or cancer therapy drug.More specifically, be the slow releasing agent of anti entity tumour, be mainly sustained-release implant and slow releasing injection.The topical application glucocorticoid can suppress or alleviate the local organization edema effectively, and can increase the sensitivity of tumor cell to cancer therapy drug; This controlled release formulation for anti entity tumour also effectively reduces tension force, a matter pressure, the matter viscosity in the tumor, and then improves its interstitial fluid conductance, helps medicine and enters entity tumor and the effective diffusion in tumor.
In addition, with glucocorticoid and or cancer therapy drug make drug level that slow releasing agent (being mainly slow releasing injection and sustained-release implant) not only can greatly improve tumor by local, reduce the drug level of medicine in blood circulation, reduce the toxicity of medicine normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.The above unexpected main contents of the present invention of finding to constitute.
Controlled release formulation for anti entity tumour of the present invention comprises anticancer effective component and pharmaceutic adjuvant, and anticancer effective component is selected from platinum-like compounds and glucocorticoid.
Compound medicament composition of the present invention can be made into any dosage form, as, but be not limited to capsule, slow releasing agent, granule, pill, tablet, powder, injection, ointment, patch, implant, slow releasing agent implant, slow releasing agent injection etc.Wherein be preferred with the slow releasing agent, with slow releasing agent implant and slow releasing agent injection for most preferably.
A kind of preferred form of the present invention is a slow releasing injection, is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 40-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Anticancer effective component be glucocorticoid or and platinum-like compounds; Slow-release auxiliary material range of viscosities IV (dl/g) is 0.1～0.8, be selected from poly-dl-lactide (D, L-PLA), poly-dl-lactide/ethanol copolymer (D, L-PLGA), monomethyl polyethylene glycol (MPEG-PLA), monomethyl polyethylene glycol copolymer (MPEG-PLGA), polyethylene glycol (PLA-PEG-PLA), polyethylene glycol copolymer (PLGA-PEG-PLGA), end carboxyl polylactic acid (PLA-COOH), end carboxyl polylactic acid/ethanol copolymer (PLGA-COOH), polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer decanedioic acid) [P (EAD-SA)], poly-(fumaric acid decanedioic acid) [P (FA-SA)], polylactic acid (PLA), the copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), poly-to dioxy cyclohexanone (PDO), PTMC (PTMC), xylitol, oligosaccharide, chrondroitin, chitin, chitosan, hyaluronic acid, collagen protein, gelatin, poloxamer, one of albumin glue or its combination; Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
Conventional route administrations such as main oral administration of platinum family cancer therapy drug or intravenous injection, administering mode of the present invention is the local sustained release administration, obviously reduces the toxic action of its whole body in the therapeutic effect that significantly strengthens medicine.The platinum-like compounds of having reported of using through the slow release approach has cisplatin and carboplatin etc., yet existing several thousand new platinum family chemical compounds are entered the screening back to be found, have only 28 chemical compounds to enter clinical research, there are 4 chemical compounds to get the Green Light and come into the market, also have 2～3 chemical compounds will obtain to produce certification.Therefore, in having the platinum-like compounds of active anticancer, be not all slow release effects that all can in slow-release auxiliary material of the present invention, reach effective release yet.Pharmaceutic adjuvant have hundreds of more than, pharmaceutic adjuvant with slow releasing function, it is not apparent particularly selected platinum-like compounds among the present invention slowly being discharged in the regular hour in human body or animal body, but specific slow-release auxiliary material need could be determined through a large amount of creative works with the selection of slow releasing pharmaceutical combination.Discharge overfill and be not enough to obtain active drug concentration, thereby effective tumor killing cell; Can cause prominent releasing if discharge, then cause the whole province's toxic reaction as conventional injection easily.The data of release characteristics need could obtain through a large amount of creationary experiments in inside and outside in the related data, particularly animal body, are not just can determine to have unobviousness through limited experiment.
Glucocorticoid can help obviously also that medicine enters entity tumor and around tumor and infiltration and diffusion in the tumor tissues except that having the effect that suppresses growth of tumour cell.
Platinum-like compounds is selected from one of following or combination: cisplatin (cisplatin, DDP), carboplatin (Carboplatin, carboplatin), ring platinum (Cycloplatin), platinum in heptan (sunplatinum), DNA-2114 (dacarbazine; Dacarbazine; NSC-45388; Dacarbazine), cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin (Enloplatin), sulfatodiamino cyclohexane platinum (ring ethylenediamine platinic sulfate, Sulfatodiaminocy clohexane platinum, SHP), Spiroplatin (spiral shell sulphur platinum amine), dexormaplatin (Dexormaplatin), iproplatin (Iproplatin), lobaplatin (Lobaplatin, happy platinum), rice platinum (Miboplatin), pick up platinum (picoplatin), nedaplatin (Nedaplatin), ormaplatin (Ormaplatin), oxaliplatin (Oxaliplatin, Oxaloplatin), sebriplatin (Sebriplatin, briplatin), spiroplatin (Spiroplatin), platinum (sunpla) relaxes, bicycloplatin (bicycloplatin), according to platinum (eptalatin), picoplatin, citricplatin (citricplatin), ZD 0473 (picoplatin) or zeniplatin (Zeniplatin).
Above platinum-like compounds with cisplatin, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin or oxaliplatin serve as preferred.
Above-mentioned platinum-like compounds shared ratio in compositions is decided because of concrete condition, can be 0.1%-50%, is good with 1%-30%, and 5%-20% is best.
The selectable glucocorticoid medicine of the present invention comprises, but be not limited to, cortisone (cortisone), hydrocortisone (hydrocortisone), hydrocortisone acetate (hydrocortisone acetate), hydrocortisone butyrate (hydrocortisone butyrate), prednisone (Prednisone), meticortelone (prednisolone), methyl meticortelone (Methylprednisolone), omcilon (triamcinolone acetonide, triamcinolone Triamcinolone, Triamcinolone, triamcinolone, Fluoxyprednisolone, Triamcortisone), dexamethasone (dexamethasone), betamethasone (Betemethasone), clobetasone butyrate (clobetasone butyrate), clobetasol propionate (clobetasol propionate, chlorine times Mi Song, dermovate), beclometasone (Beclomethasone, the Beclomethasone, beclomethasone dipropionate, Beclomethasone, Beclomethasone Dipropionate), triamcinolone acetonide (Triamcinolone Acetonide, triamcinolone acetonide, Triamcinolone Acetonide, Triamcinolone Acetonide, Adcortyl A), pivalic acid dexamethasone (flumethasone pivalate), momestasone furoate (mometasone furoate), valeric acid Tuo Tamisong (betamethasone valerate), betamethasone dipropionate (betamethasone dipropionate), fluocinonide (flucinonode), halcinonidedcorten (halcinonide, halcinonide Halcinonide, halcinonide)), sicorten see halometasone (halmetasone), beclomethasone (BDP), budesonide (BUD) and fluticasone.
Glucocorticoids also comprises available salt and ester, as, but be not limited to acetic acid, butanoic acid, sodium succinate, diacetate, phosphoric acid, propanoic acid, hydrochlorate or ester etc.
Above-mentioned glucocorticoid medicine is divided into basic, normal, high effect according to its effect power, it is generally acknowledged, poor efficiency is mainly cortisone and hydrocortisone, and consumption per day is about 1-50mg; The middle effect is mainly prednisone, meticortelone, methyl meticortelone and omcilon, and consumption per day is 0.1-10mg; Efficiently be mainly betamethasone and dexamethasone, consumption per day is 0.01-5mg.
The present invention selects according to its clinical consumption, it is divided into following a few class, (1) poor efficiency class: include, but not limited to cortisone, hydrocortisone, hydrocortisone acetate, prednisone; (2) imitate class in: include, but not limited to meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide; (3) efficient class: include, but not limited to pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide, fluticasone.
The application dose of above-mentioned glucocorticoid medicine is decided as the case may be, and when it is generally acknowledged the clinical system consumption, the consumption per day of poor efficiency class is about 1-50mg; Middle effect consumption per day is 0.1-10mg; Efficient consumption per day is 0.01-5mg.Consumption of the present invention can be, but is not limited to, and 0.1 to 10 times of above-mentioned consumption per day serves as preferred with 0.1 to 5 times, serves as preferred with 0.1 to 5 times.
Cancer therapy drug in medicament slow-release microsphere only is platinum-like compounds or glucocorticoid, and the application of slow-releasing anticarcinogen injection and potentiation mode are:
(1) contain the slow releasing injection local injection of platinum-like compounds, glucocorticoid is used through other approach;
(2) local injection contains the slow releasing injection of glucocorticoid, and other approach are used platinum-like compounds;
(3) local injection contains the slow releasing injection and the slow releasing injection that contains glucocorticoid of platinum-like compounds; Or
(4) local injection contains the slow releasing injection of platinum-like compounds and synergist.
The slow-releasing anticarcinogen injection of topical application also is used for the potentiation to radiotherapy or other therapies.Other approach refer to, but are not limited to tremulous pulse, vein, abdominal cavity, subcutaneous, intracavitary administration.
Glucocorticoid shared ratio in compositions is decided because of concrete condition, can be 0.01%-50%, is good with 0.1%-40%, and 1%-30% is best.The poor efficiency glucocoricoid is got near upper limit numerical value, and middle effect class is got intermediate value, and efficient class is got near lower limit numerical value.
The weight ratio of platinum-like compounds and glucocorticoid is 1-99: 1 to 1: 1-99.
Anticancer effective component in the slow-releasing anticarcinogen injection microsphere of the present invention is preferably as follows, and all is weight percentage:
(1) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone; Or
(2) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, the pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, the Beclomethasone, sicorten see halometasone, beclomethasone, the cisplatin of budesonide or fluticasone and 1-30%, carboplatin, ring platinum, heptan platinum, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin, platinum relaxes, bicycloplatin, according to platinum, picoplatin, citricplatin, the combination of ZD 0473 or zeniplatin.
Slow-release auxiliary material is selected from poly-dl-lactide, poly-dl-lactide/ethanol copolymer, the monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, the polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer decanedioic acid), poly-(fumaric acid decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, the copolymer of polyglycolic acid and hydroxyacetic acid, xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, one of poloxamer and albumin glue or its combination.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release micro-spheres of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer;
(5) combination of the PLGA of the PLA of the polifeprosan of 30-60% and 30-60% or 30-60%;
(6) xylitol of 40-95%, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, poloxamer or white tempera; Or
(7) poly-dl-lactide of 40-95%, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
In various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, glycolic and hydroxy carboxylic acid, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is polifeprosan [poly-(1,3-two (to the carboxyl phenoxy group) propane decanedioic acid) (p (CPP-SA)), bis-fatty acid decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer decanedioic acid) [P (EAD-SA)] and poly-(fumaric acid decanedioic acid) [P (FA-SA)] etc.Content during to carboxylic phenoxypropane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, and the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
The molecular weight peak value of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 5,000-30,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 5,000-50,000 is preferred, with 10,000-30,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 5000-100,000, but with 20,000-60,000 be preferably, with 30,000-50,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 1000 to 30000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 30000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 20000 to 30000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.Used polylactic acid serves as preferred with Poly-L-lactic acid (L-PLA).Poly-L-lactic acid (L-PLA) range of viscosities IV (dl/g) is 0.2～0.8, and glass transition temperature range is 55～65 ℃, 175～185 ℃ of fusing points.
Except that above-mentioned adjuvant, also can select for use other materials to see the United States Patent (USP) (patent No. 4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.
In the slow releasing injection, drug sustained release system can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller, makes the injection use then with after the injection solvent mixes.In various slow releasing injection, serve as preferred with the suspension type slow releasing injection, the suspension type slow releasing injection is the preparation that the drug sustained release system that will contain anticancer component is suspended in gained in the injection, used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt.The purpose of suspending agent is the pastille microsphere that effectively suspends, thereby is beneficial to the usefulness of injection.
Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The content of suspending agent in common solvent is decided because of its characteristic, can be 0.1-30% and decides because of concrete condition.Consisting of of preferred suspending agent:
A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80; Or
B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or.
C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
The kind of solvent is then depended in the preparation of solvent, and common solvent has commercially available, also can make by oneself, and as distilled water, water for injection, physiology buffer towards liquid, dehydrated alcohol or the preparation of various salt, but must be in strict accordance with related standards.Special solvent need be considered the kind of suspending agent and the medicine that composition, solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule) and the preparation method of injection, as sodium carboxymethyl cellulose (1.5%)+mannitol and/or sorbitol (15%) and/or soil temperature 80 (0.1%) are dissolved in the normal saline corresponding solvent, viscosity is at 10cp-650cp (20 ℃-30 ℃ time).
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).This viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
The preparation method of slow releasing injection is arbitrarily, available some kinds of methods preparation: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are made micropowder, liposome bag medicine method and emulsion process etc. in conjunction with freezing (drying) comminuting method.Serve as preferred wherein with dissolution method (being the solvent volatility process), seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection, and its method is arbitrarily.The particle size range of used microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Microsphere also can be used for preparing other slow releasing injection, as gel injection, block copolymer micelle injection.Wherein, block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, used pharmaceutic adjuvant can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) is 10/90-90/10 (weight) with the blend ratio of polyglycolic acid, preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.The volume size depends on factors such as the position, size of focus.Can be the bar-shaped of 0.1-5mm (slightly) * 1-10mm (length), also can be other shapes such as lamellar.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
Anticancer effective component in the sustained-release implant can be with reference to slow releasing injection, but is preferably as follows:
(1) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone; Or
(2) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, the pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, the Beclomethasone, sicorten see halometasone, beclomethasone, the cisplatin of budesonide or fluticasone and 1-30%, carboplatin, ring platinum, heptan platinum, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin, platinum relaxes, bicycloplatin, according to platinum, picoplatin, citricplatin, the combination of ZD 0473 or zeniplatin.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release implant of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer;
(5) combination of the PLGA of the PLA of the polifeprosan of 30-60% and 30-60% or 30-60%;
(6) xylitol of 40-95%, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, poloxamer or albumin glue; Or
(7) poly-dl-lactide of 40-95%, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
When the cancer therapy drug in the medicament slow-release microsphere only is platinum-like compounds or its synergist, the application of anti-cancer sustained-released implantation agent and the same slow releasing injection of potentiation mode.
Route of administration depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.
The application of sustained-release implant and the same slow-releasing anticarcinogen injection of potentiation mode, the cancer therapy drug that place the associating of the chemical-therapy synergistic agent of the associating of the cancer therapy drug of the promptly local chemical-therapy synergistic agent of placing and other administration, the local cancer therapy drug of placing and other administration, part and the associating of the local chemical-therapy synergistic agent of placing.Wherein the cancer therapy drug of topical application and chemical-therapy synergistic agent can be separately or Joint Production, packing, sale, use.Packing refers to medicine carrying process and pastille slow-release agent the exterior and interior packing for transport and/or store of medicine for adjuvant.The medicine carrying process includes, but not limited to weighing, dissolving, mixing, drying, shaping, coating, spraying, granulation etc.
The clinical practice dosage of cancer therapy drug depends on patient's concrete condition, can be from 0.1 to 300mg/kg body weight, and 1 to 200mg/kg is preferred, 10 to 100mg/kg for there being most choosing.And one of percentage that the consumption of hormone is only measured for this reason is to 1/10th.
The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, be mainly slow releasing injection or sustained-release implant, the indication tumor comprises former or cancer or sarcoma or the carcinosarcoma that shifts that originates from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.Be particularly suitable for treating brain and central nervous system's tumor.
Preferred example application as, contain dexamethasone and carboplatin, along primary or the compositions of oxaliplatin be used for the treatment of entity tumors such as the cerebral tumor, cerebral glioma particularly.
Also can add other medicinal ingredient in slow releasing injection that the present invention is made or the sustained-release implant, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment technical method of the present invention is further described:
Test 1, different modes compare the effect of local edema after using hormone
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 1 cm diameter its grouping.Every group of dosage is the 1mg/kg dexamethasone.Measure medicament contg (%) in the different time tumor, the result shows, the local drug concentration significant difference of dexamethasone after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.This discovery constitutes key character of the present invention.Following relevant inhibition test has further confirmed this point.
The interior tumor-inhibiting action of body that test 2, different modes are used behind the dexamethasone compares
With the rat is subjects, with 2 * 10
5Individual oophoroma tumor cell subcutaneous injection is in its hypochondrium, treats behind tumor growth to 0.5 cm diameter its grouping.Every group of dosage is the 0.5mg/kg dexamethasone.The treatment back was measured gross tumor volume size, relatively therapeutic effect on the 21st day.The result shows, the tumor-inhibiting action significant difference of dexamethasone after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.Good effect not only, toxic and side effects is also little.
Test 3, contain tumor-inhibiting action in the body of platinum-like compounds and glucocorticoid (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and medicine is all through intratumor injection.The dosage of glucocorticoid is 0.5mg/kg, and platinum-like compounds is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 21st day.
Table 1
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1 (6) | Contrast | 50±10 | |
| 2 (6) | Glucocorticoid | 40±5.0 | ＜0.05 |
| 3 (6) | Cisplatin | 38±4.8 | ＜0.01 |
| 4 (6) | Carboplatin | 36±5.4 | ＜0.01 |
| 5 (6) | Heptan platinum | 40±5.0 | ＜0.01 |
| 6 (6) | DNA-2114 | 38±3.0 | ＜0.01 |
| 7 (6) | Glucocorticoid+cisplatin | 20±2.2 | ＜0.001 |
| 8 (6) | Glucocorticoid+carboplatin | 22±3.6 | ＜0.001 |
| 9 (6) | Glucocorticoid+heptan platinum | 16±3.2 | ＜0.001 |
| 10 (6) | Glucocorticoid+DNA-2114 | 20±3.2 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for platinum-like compounds (cisplatin, carboplatin, heptan platinum, DNA-2114) and used glucocorticoid (dexamethasone), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 4, platinum-like compounds and glucocorticoid (slow releasing injection)
Used tumor cell comprises CNS-1, C6, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT) etc.Medicine is through intratumor injection.Therapeutic effect (seeing Table 2).Glucocorticoid dosage is 0.25mg/kg, and cancer therapy drug is 10mg/kg.The treatment back was measured the gross tumor volume size on the 20th day, made relatively therapeutic effect (seeing Table 2) of index with inhibition rate of tumor growth (%).
Table 2
| Oncocyte | Citricplatin | Lobaplatin | Nedaplatin | Glucocorticoid | Citricplatin+glucocorticoid | Lobaplatin+glucocorticoid | Nedaplatin+glucocorticoid |
| CNS | 44％ | 30％ | 52％ | 40％ | 88％ | 80％ | 76％ |
| C6 | 34％ | 44％ | 40％ | 34％ | 84％ | 80％ | 84％ |
| SA | 34％ | 60％ | 50％ | 32％ | 86％ | 72％ | 92％ |
| BC | 36％ | 62％ | 54％ | 34％ | 94％ | 82％ | 80％ |
| BA | 38％ | 50％ | 62％ | 30％ | 92％ | 72％ | 72％ |
| LH | 42％ | 56％ | 62％ | 48％ | 90％ | 86％ | 84％ |
| PAT | 44％ | 52％ | 66％ | 42％ | 80％ | 88％ | 78％ |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum-like compounds (lobaplatin, nedaplatin, citricplatin) and glucocorticoid (betamethasone), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 5, platinum-like compounds and glucocorticoid (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual tumor cell of liver subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 3).First group is contrast, and the 2nd to 10 group is the treatment group, and sustained-release implant is placed in tumor.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 14th day.
Table 3
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1 (6) | Contrast | 52±8 | |
| 2 (6) | Glucocorticoid | 38±6.0 | ＜0.05 |
| 3 (6) | Ormaplatin | 40±6.2 | ＜0.01 |
| 4 (6) | Spiroplatin | 36±5.6 | ＜0.001 |
| 5 (6) | Sebriplatin | 36±4.2 | ＜0.01 |
| 6 (6) | Oxaliplatin | 32±5.0 | ＜0.001 |
| 7 (6) | Glucocorticoid+ormaplatin | 22±3.6 | ＜0.01 |
| 8 (6) | Glucocorticoid+spiroplatin | 22±4.4 | ＜0.001 |
| 9 (6) | Glucocorticoid+sebriplatin | 20±3.4 | ＜0.01 |
| 10 (6) | Glucocorticoid+oxaliplatin | 16±2.6 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum-like compounds (ormaplatin, oxaliplatin, sebriplatin, spiroplatin) and glucocorticoid (hydrocortisone), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 6, platinum-like compounds and glucocorticoid (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual pulmonary carcinoma tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group (platinum-like compounds or glucocorticoid) and therapeutic alliance group (platinum-like compounds and glucocorticoid).Platinum-like compounds is through intratumor injection, and glucocorticoid is through lumbar injection.Glucocorticoid dosage is 20mg/kg, and cancer therapy drug is 4mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 4) of index with inhibition rate of tumor growth.
Table 4
| Test group (n) | Suffered treatment | Suppression ratio (%) | The P value |
| 1 (6) | Contrast | - | |
| 2 (6) | Glucocorticoid | 30 | ＜0.05 |
| 3 (6) | Platinum relaxes | 46 | ＜0.01 |
| 4 (6) | Bicycloplatin | 58 | ＜0.01 |
| 5 (6) | According to platinum | 40 | ＜0.01 |
| 6 (6) | Picoplatin | 58 | ＜0.01 |
| 7 (6) | Glucocorticoid+platinum relaxes | 80 | ＜0.001 |
| 8 (6) | Glucocorticoid+bicycloplatin | 84 | ＜0.001 |
| 9 (6) | Glucocorticoid+according to platinum | 70 | ＜0.001 |
| 10 (6) | Glucocorticoid+picoplatin | 84 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum-like compounds (platinum that relaxes, bicycloplatin, according to platinum, picoplatin) and glucocorticoid (triamcinolone acetonide), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 7, platinum-like compounds and glucocorticoid (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Platinum-like compounds is through lumbar injection, and methyl meticortelone is through intratumor injection.Methyl meticortelone dosage is 20mg/kg, and cancer therapy drug is 5mg/kg.The treatment back was measured the gross tumor volume size on the 20th day, make relatively therapeutic effect of index with inhibition rate of tumor growth, above result shows, methyl meticortelone obviously strengthens the inhibitory action to the growth of kinds of tumors such as pulmonary carcinoma, the cerebral tumor, cancer of pancreas, carcinoma of prostate such as cisplatin, carboplatin, heptan platinum, DNA-2114, enloplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, wherein to the potentiation the most obviously (P＜0.01) of cisplatin, carboplatin, heptan platinum, DNA-2114, lobaplatin, nedaplatin and oxaliplatin.
The tumor-inhibiting action of test 8, platinum-like compounds and glucocorticoid (sustained-release implant)
With the rat is subjects, with 2 * 10
5Individual pancreatic cancer cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Sustained-release implant is all placed in tumor.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect of index with inhibition rate of tumor growth.Above result shows, glucocorticoid (methyl meticortelone) obviously strengthens the inhibitory action (P＜0.01) to cancer of pancreas such as cisplatin, carboplatin, heptan platinum, DNA-2114, lobaplatin, nedaplatin and oxaliplatin.
The tumor-inhibiting action of test 9, platinum-like compounds and glucocorticoid (sustained-release implant)
By testing 8 described methods mensuration platinum-like compounds and glucocorticoid (sustained-release implant) tumor-inhibiting action to colon cancer, above result shows, glucocorticoid (meticortelone) obviously strengthens the tumor-inhibiting action (P＜0.01) of cisplatin, carboplatin, heptan platinum, DNA-2114, lobaplatin, nedaplatin or oxaliplatin etc.
Same result also sees and uses cortisone, prednisone, meticortelone, clobetasone butyrate, hydrocortisone butyrate, omcilon, momestasone furoate, fluocinonide, the pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, the Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone are to cisplatin, the card ripple, heptan platinum, DNA-2114, lobaplatin, nedaplatin or oxaliplatin are to the cerebral tumor, carcinoma of prostate, thymic carcinoma, the potentiation of esophageal carcinoma.
The test 10, the different molecular weight polylactic acid make according to release ratio in the body of platinum sustained-release implant
With the rat is subjects, grouping (3/group) and in the equivalent of subcutaneous polylactic acid (PLA) carrying that contains different molecular weight (MW) according to the platinum sustained-release implant.Survey the surplus of medicine in implant respectively at 1,3,7,14,21,28 and 35 day then, and then draw rate of release (%) in its body.The result shows, molecular weight is 20000 is released to: 1 day (8%), 3 (28%), 7 (56%), 14 (82%), 21 (90), 28 (94) and 35 (98%).What relatively the different molecular weight polylactic acid was made finds according to discharging in the body of platinum sustained-release implant, slack-off with the molecular weight increase, with the 7th day was example, compare with whole body administration group, tumor control rate increases with the polylactic acid molecule amount and improves, and is followed successively by 68% (MW:5000), 66% (MW:15000), 54% (MW:25000), 50% (MW:40000) and 48 (MW:60000).
It is platinum in heptan, DNA-2114, lobaplatin, nedaplatin, oxaliplatin, citricplatin, ZD 0473, easypro platinum, bicycloplatin or glucocorticoid (dexamethasone) slow releasing agent that adjuvant is made that same result also sees with polylactic acid.
That pays special attention to is simple to operation, the good reproducibility of slow releasing agent of the present invention, particularly slow releasing injection.Good effect not only, toxic and side effects is little.
Different drug packages is to want characteristic different with different Biodegradable high moleculars.Discover that further the slow-release auxiliary material that is most appropriate to medicament slow release of the present invention is a poly-dl-lactide, poly-dl-lactide/ethanol copolymer, the monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, the polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer decanedioic acid), poly-(fumaric acid decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, the copolymer of polyglycolic acid and hydroxyacetic acid, xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, poloxamer, one of albumin glue or its combination; Optimum suspending agent is one of methylcellulose, hydroxy methocel, sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40, soil temperature 80 or its combination.
In a word, growth all had the obvious suppression effect to kinds of tumor cells when used platinum-like compounds and glucocorticoid were used separately, can show significant potentiation when use in conjunction.Therefore, effective ingredient of the present invention is the combination of glucocorticoid or any one (or more than one) platinum-like compounds and glucocorticoid.The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.
Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.
(4) specific embodiment
Embodiment 1.
80mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg cisplatin and 10mg prednisone, shake up the back contains 10% cisplatin and 10% prednisone with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection.The viscosity of this injection is 150cp-400cp (20 ℃-30 ℃ time), and the drug release time in external normal saline is 25-30 days, is about 25-30 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that used polifeprosan is 50: 50, contains anticancer effective component and percentage by weight thereof and is:
(1) cortisone of 5-20%, hydrocortisone, hydrocortisone acetate or prednisone; Or
The cisplatin of (2) 10% cortisones, hydrocortisone, hydrocortisone acetate or prednisone and 1-30%, carboplatin, ring platinum, heptan platinum, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin, the platinum that relaxes, bicycloplatin, according to the combination of platinum, picoplatin, citricplatin, ZD 0473 or zeniplatin.
Embodiment 3.
With 80mg molecular weight (MW) peak value is that the polylactic acid (PLA) of 10000-25000 is put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 15mg carboplatin and 5mg meticortelone, shakes up the dry organic solvent of removing of final vacuum again.Dried pastille solid composite freezing and pulverizing is made the micropowder that contains 15% carboplatin and 5% meticortelone, be suspended in then in the normal saline that contains 1.5% sodium carboxymethyl cellulose, make corresponding suspension type slow releasing injection.The viscosity of this slow releasing injection is 160cp-440cp (20 ℃-30 ℃ time), and the drug release time in external normal saline is 20-35 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 4
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that the molecular weight peak value is the polylactic acid (PLA) of 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) meticortelone of 2-10%, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate or dexamethasone; Or
(2) cisplatin of the meticortelone of 2-10%, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate or dexamethasone and 1-30%, carboplatin, heptan platinum, DNA-2114, dexormaplatin, nedaplatin, ormaplatin or oxaliplatin combination.
Embodiment 5.
With 85mg molecular weight peak value is the polylactic acid (PLGA of 40000-60000,50: 50) put into container, after adding 100 milliliters of dichloromethane dissolving mixings, add 10 milligrams of cisplatin and 5 milligrams of betamethasones, shake up the back contains 10% cisplatin and 5% betamethasone with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the injection that contains the 5-15% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 20-55 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method step that is processed into slow releasing injection is identical with embodiment 5, but different is that PLGA is 50: 50, the molecular weight peak value is 20000-40000, and contained anticancer effective component is: methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate or the fluocinonide of (1) 5-20%; Or the carboplatin of methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate or the fluocinonide of (2) 5-20% and 1-40%, heptan platinum, DNA-2114, nedaplatin or the combination of oxaliplatin.
Embodiment 7.
With 40mg polifeprosan (20: 80) and 30mg molecular weight peak value is the polylactic acid (PLGA of 40000-60000,50: 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg nedaplatin and 20mg dexamethasone, shake up the back contains 10% nedaplatin and 20% dexamethasone with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but different is that polifeprosan is 30: 70) and PLGA be 50: 50, MW is 20000-40000; Contained anticancer effective component is:
(1) meticortelone of 20-30%, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone or betamethasone; Or
(2) combination of the meticortelone of 20-30%, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone or betamethasone and 10% cisplatin, carboplatin, nedaplatin, ormaplatin or oxaliplatin.
Embodiment 9
With 40mg polifeprosan (20: 80), 30mg molecular weight peak value is that the polylactic acid (PLA) of 20000-40000 is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg nedaplatin and 10mg dexamethasone, shake up the back contains 20% nedaplatin and 10% dexamethasone with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 20-25 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 10
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is that polifeprosan is 50: 50) and the molecular weight peak value be the PLA of 10000-20000, contained anticancer effective component is: 25% dexamethasone and 10% cisplatin, carboplatin, heptan platinum, DNA-2114, nedaplatin, ormaplatin or oxaliplatin combination.
Embodiment 11
75mg polifeprosan (50: 50) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 5mg omcilon and 20mg oxaliplatin, shake up the back contains 5% omcilon and 20% oxaliplatin with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is that contained anticancer effective component is:
(1) omcilon of 1-10%, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone;
(2) combination of cisplatin, carboplatin, nedaplatin or the oxaliplatin of the omcilon of 1-10%, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone and 5-20%.
Embodiment 13
With 78mg molecular weight peak value is that poly-(erucic acid dimer decanedioic acid) copolymer (50: 50) of 40000-60000 is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg carboplatin and 2mg halcinonidedcorten, shake up the back contains 20% carboplatin and 2% halcinonidedcorten with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 25-30 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 14
The method step that is processed into sustained-release implant is identical with embodiment 11,13, and used adjuvant is poly-(fumaric acid decanedioic acid) copolymer (40: 60) but different is, the molecular weight peak value is 20000-40000, contains anticancer effective component to be:
(1) omcilon of 0.1-10%, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone;
(2) combination of cisplatin, carboplatin, nedaplatin or the oxaliplatin of the omcilon of 0.1-5%, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone and 2-20%.
Embodiment 15
The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:
A) the molecular weight peak value is the polylactic acid (PLA) of 5000-10000,10000-30000,30000-60000,60000-100000 or 100000-150000;
B) the molecular weight peak value is the polyglycolic acid of 5000-10000,10000-30000,30000-60000,60000-100000 or 100000-150000 and the copolymer of hydroxyacetic acid (PLGA), wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;
C) combination of polifeprosan and PLA or PLGA;
D) 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) copolymer (polifeprosan);
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer decanedioic acid) copolymer;
G) poly-(fumaric acid decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin, poloxamer or albumin glue;
I) poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Embodiment 16
The method step that is processed into slow releasing injection is identical with embodiment 1-15, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20.
Embodiment 17
The method step that is processed into slow releasing injection is identical with embodiment 11-15, but different is that contained anticancer effective component is:
(1) cortisone of 10-30%, hydrocortisone, hydrocortisone acetate or prednisone;
(2) meticortelone of 5-20%, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate or fluocinonide;
(3) the pivalic acid dexamethasone of 0.1-10%, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone;
(4) cortisone of 10-30%, hydrocortisone, hydrocortisone acetate or prednisone and with the combination of cisplatin, carboplatin, nedaplatin or the oxaliplatin of 10-30%.
(5) combination of the cisplatin of the meticortelone of 5-20%, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate or fluocinonide and 10-20%, carboplatin, nedaplatin or oxaliplatin;
(6) combination of cisplatin, carboplatin, nedaplatin or the oxaliplatin of the pivalic acid dexamethasone of 0.1-10%, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone and 5-10%.
The foregoing description illustrates for example rather than will limit scope of the present invention.In fact, to those skilled in the art all can be from description and chart apparent except that shown in this paper and the of the present invention various changes described, as, used organic solvent can be acetone, dehydrated alcohol, chloroform etc.Certainly these change the scope of not leaving appended claim.
Therefore, to disclose some specific implementations of the present invention emphatically and its being equal to of making is changed or replaces all be in described design of appended claims and scope to the description that should be realized that the front.The present invention disclosed and the protection the content see claim.
Claims (10)
1. the anticancer pharmaceutical composition of loaded with platinum compound and glucocorticoid is characterized in that this anticancer pharmaceutical composition is a slow releasing injection, is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 40-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Anticancer effective component is the combination of glucocorticoid or glucocorticoid and platinum-like compounds;
Suspending agent is selected from one of sodium carboxymethyl cellulose, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination;
Slow-release auxiliary material range of viscosities IV (dl/g) is 0.1～0.8, is selected from one of following or its combination:
A) polylactic acid;
B) copolymer of polyglycolic acid and hydroxyacetic acid;
C) polifeprosan;
D) combination of the copolymer of polifeprosan and polylactic acid or polyglycolic acid and hydroxyacetic acid;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, poloxamer or albumin glue;
I) poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), is selected from one of sodium carboxymethyl cellulose, hydroxy methocel, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
2. the slow-releasing anticarcinogen injection according to claim 1, it is characterized in that platinum-like compounds be selected from cisplatin, carboplatin, ring platinum, heptan platinum, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin, the platinum that relaxes, bicycloplatin, according to platinum, picoplatin, citricplatin, ZD 0473 or zeniplatin.
3. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that glucocorticoid is selected from cortisone, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, the pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, the Beclomethasone, sicorten see halometasone, beclomethasone, a kind of or its combination in budesonide or the fluticasone.
4. the slow-releasing anticarcinogen injection according to claim 1, the weight ratio that it is characterized in that platinum-like compounds and glucocorticoid is 1-99: 1 to 1: 1-99.
5. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that the anticancer effective component of slow-releasing anticarcinogen injection and percentage by weight are:
(1) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone; Or
(2) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, the pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, the Beclomethasone, sicorten see halometasone, beclomethasone, the cisplatin of budesonide or fluticasone and 1-30%, carboplatin, ring platinum, heptan platinum, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin, platinum relaxes, bicycloplatin, according to platinum, picoplatin, citricplatin, the combination of ZD 0473 or zeniplatin.
6. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that the molecular weight peak value of polylactic acid in the selected slow-release auxiliary material is selected from 5000-10000,10000-30000,300000-60000,60000-100000 or 100000-150000; The ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50; The molecular weight peak value is 5000-10000,10000-30000,300000-60000,60000-100000 or 100000-150000; In the polifeprosan, it is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to the composition weight ratio of carboxy phenyl propane and certain herbaceous plants with big flowers diacid.
7. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20;
F) iodine glycerol, simethicone, propylene glycol or carbomer;
G) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80;
H) 5-20% mannitol+0.1-0.5% soil temperature 80; Or
I) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
8. the slow-releasing anticarcinogen injection according to claim 1, it is characterized in that being used for anticancer effective component is used for preparation treatment and originates from people and animal brain, the central nervous system, kidney, liver, gallbladder, incidence, the oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, the uterus, ovary, endometrium, cervix uteri, prostate, bladder, former or the cancer of secondary of colon or rectum, the suspensoid injectio of sarcoma or carcinosarcoma or sustained-release implant are in tumor or tumor week injection or place administration.
9. described according to Claim 8 anti-cancer sustained-released implantation agent is characterized in that being used for anticancer effective component and is:
(1) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, Beclomethasone, sicorten see halometasone, beclomethasone, budesonide or fluticasone; Or
(2) cortisone of 0.01%-50%, hydrocortisone, hydrocortisone acetate, prednisone, meticortelone, methyl meticortelone, clobetasone butyrate, hydrocortisone butyrate, dexamethasone, betamethasone, omcilon, triamcinolone acetonide, momestasone furoate, fluocinonide, the pivalic acid dexamethasone, valeric acid Tuo Tamisong, betamethasone dipropionate, halcinonidedcorten, chlorine times Mi Song, the Beclomethasone, sicorten see halometasone, beclomethasone, the cisplatin of budesonide or fluticasone and 1-30%, carboplatin, ring platinum, heptan platinum, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, pick up platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin, platinum relaxes, bicycloplatin, according to platinum, picoplatin, citricplatin, the combination of ZD 0473 or zeniplatin.
10. described according to Claim 8 anti-cancer sustained-released implantation agent is characterized in that being used for slow-release auxiliary material and is one of following or its combination:
A) polylactic acid, molecular weight peak value are 10000-30000,300000-60000,60000-100000 or 100000-150000;
B) copolymer of polyglycolic acid and hydroxyacetic acid, wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50, the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
C) combination of the copolymer of polifeprosan and polylactic acid or polyglycolic acid and hydroxyacetic acid;
D) polifeprosan, to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid);
G) poly-(fumaric acid-decanedioic acid);
H) xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, poloxamer or white tempera;
I) poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006102013942A CN101023918A (en) | 2006-12-26 | 2006-12-26 | Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006102013942A CN101023918A (en) | 2006-12-26 | 2006-12-26 | Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101023918A true CN101023918A (en) | 2007-08-29 |
Family
ID=38742768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006102013942A Pending CN101023918A (en) | 2006-12-26 | 2006-12-26 | Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101023918A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177959A (en) * | 2016-04-01 | 2016-12-07 | 北京大学 | Anti-cancer composition and preparation thereof and application |
-
2006
- 2006-12-26 CN CNA2006102013942A patent/CN101023918A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177959A (en) * | 2016-04-01 | 2016-12-07 | 北京大学 | Anti-cancer composition and preparation thereof and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101081206A (en) | Anti-cancer medicine composition containing tyrosine kinase restraining agent | |
| CN101084876A (en) | Anti-cancer composition containing bendamustine | |
| CN100464736C (en) | Slow released anticancer injection with both antimetabolite and its synergist | |
| CN101502484B (en) | Glucocorticosteroid and chemotherapy medicament carried by anticancer sustained-release agent | |
| CN101023918A (en) | Anti-cancer medicine composition carried with platinum-like compounds and glucocorticoid hormone | |
| CN100569289C (en) | The anticancer pharmaceutical composition of loaded with platinum compound and clofarabine | |
| CN101023921A (en) | Anti-cancer composition containing glucocorticoid hormone | |
| CN100998555A (en) | Slow-release anticarcinogen containing vasoinhibitor | |
| CN101006981A (en) | Slow released injection containing taxane and platinum | |
| CN101023919A (en) | Entity-tumor-resistant slow-release agent | |
| CN101234084A (en) | Fluorouracil containing anti-cancer sustained-release injection | |
| CN101301472A (en) | Anticancer composition containing taxane medicament and bortezomib | |
| CN101450036A (en) | Anti-cancer sustained release agent loaded with glucocorticoid and chemical curing medicine | |
| CN101219112A (en) | Compound anticancer sustained-release injection containing bendamustine | |
| CN101088491A (en) | Anticancer composition | |
| CN101011345A (en) | Slow release injection containing platinum compound and alkylating agent | |
| CN101002941A (en) | Anticarcinogen composition carried with platinum compound and vasoinhibitor | |
| CN100998591A (en) | Anticancer composition containing Epomycin and vasoinhibitor | |
| CN101023925A (en) | Anti-cancer composition containing chemical-therapy synergistic agent | |
| CN101023920A (en) | Entity-tumor-resistant medicine composition | |
| CN101002729A (en) | Slow released anticarcinogen containing vasoinhibitor | |
| CN101023922A (en) | Anti-cancer slow-release agent carried with glucocorticoid hormone and chemical therapy medicine | |
| CN1875936B (en) | Anticancer sustained release agent containing clorfarabine and cytotoxic drug | |
| CN1969819A (en) | Anticancer pharmaceutical composition | |
| CN101023924A (en) | Entity-tumor-resistant slow-release agent containing glucocorticoid hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070829 |